Article Data

  • Views 575
  • Dowloads 107

Original Research

Open Access

Can the histopathology influence the outcome of early-stage cervical cancer?

  • J. Jonska–Gmyrek1,*,
  • A. Zolciak–Siwinska1
  • L. Gmyrek2

1The Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Department of Radiotherapy, Warsaw, Poland

2The Holy Family Hospital, Gynecological Oncology Department, Warsaw, Poland

DOI: 10.12892/ejgo2757.2016 Vol.37,Issue 2,April 2016 pp.178-181

Published: 10 April 2016

*Corresponding Author(s): J. Jonska–Gmyrek E-mail:


Purpose of investigation: The assessment of the histology influence on survival in early-stage cervical cancer patients treated with surgery. Materials and Methods: The retrospective analysis of 71 cervical adenocarcinoma (AC), International Federation of Gynecology and Obstetrics (FIGO) Stage IB, treated initially with surgery, between 1989 and 1999 and 43 squamous cell cancer (SCC) patients, treated with the same method, between 1998 and 1999, was performed. Cox multi-variant analysis and the Kaplan-Meyer methods were performed (the level of statistical significance, p ≤ 0.05). Results: The ten-year overall survival (OS) of AC and SCC patients was 67.5% and 90%, p = 0.015. The ten-year disease free survival (DFS) was 63% and 85%, p = 0.022, respectively. After adjusting the significant prognostic factors, patients with AC had significantly worse treatment outcomes than patients with SCC: DFS (relative risk (RR)1.85, 95% CI = 1.28-2.69, p = 0.001) and OS (RR 1.65, 95% CI = 1.65-2.33, p = 0.005). Conclusion: Prognosis of early cervical AC patients, treated with surgery, appears to be less favorable as compared to patients with SCC, treated with the same method.


Cervical cancer; Adenocarcinoma; Squamous cell cancer; Radiotherapy; Surgery; Treatment outcomes.

Cite and Share

J. Jonska–Gmyrek,A. Zolciak–Siwinska,L. Gmyrek. Can the histopathology influence the outcome of early-stage cervical cancer?. European Journal of Gynaecological Oncology. 2016. 37(2);178-181.


[1] Liu S., Semenciw R., Probert A., Mao Y.: “Cervical cancer in Canada: changing patterns in incidence and mortality”. Int. J. Gynecol. Cancer, 2001, 11, 24.

[2] Sasieni P., Adams J.: “Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England”. Lancet, 2001, 12, 1490.

[3] Krane J.F., Granter S.R., Trask C.E., Hogan C.L., Lee K.R.: “Papanicolau smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases”. Cancer, 2001, 93, 8.

[4] Mathew A., George P.S.: “Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix—worldwide”. Asian Pac J Cancer Prev., 2009, 10, 645.

[5] Liu S., Semenciw R., Mayo.: “Cervical cancer: the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women”. CMAJ, 2001, 164, 1151.

[6] Ayhan A., Al R.A., Baykal C., Demirtas E., Yüce K., Ayhan A.: “A comparison of prognoses of FIGO stage IB adenocarcinoma and squamous cell carcinoma”. Int J Gynecol Cancer, 2004, 14, 279.

[7] Waldenstrōm A.C., Horvath G.: “Survival of patients with adenocarcinoma of the uterine cervix in western Sweden”. Int. J. Gynecol. Cancer, 1999, 9, 18.

[8] Shingleton H.M., Bell M.C., Fremgen A., Chmiel J.S., Russell A.H., Jones W.B., Winchester D.P., Clive R.E.: “Is there a really difference in survival of women with squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma of the cervix?”. Cancer, 1995, 76, 1948.

[9] Eifel P.J, Morris M., Oswald M.J., Wharton J,T., Delclos L.: “Adenocarcinoma of the uterine cervix. Prognosis and patterns of failure in 367 cases”. Cancer, 1990, 65, 2507.

[10] Arvas. M.: “ Section IV: Invasive diseases. Early stage cervical cancers”. In: Ayhan A., Gultekin M., Dursun P.,(eds). Textbook of Gynecological Oncology. Ankara: Günes Publishing, 2010, 157.

[11] Nakanishi T., Ishikawa H., Suzuki Y., Inoue T., Nakamura S., Kuzuya K.: “A comparison of prognoses of pathologic stage Ib adenocarcinoma and squamous cell carcinoma of the uterine cervix”. Gynecol. Oncol., 2000, 79, 289.

[12] Lai C.H., Hsueh S., Hong J.H., Chang T.C., Tseng CJ., Chou H.H., et al.: “Are adenocarcinomas and adenosquamous carcinomas different from squamous carcinoma in stage IB and II cervical cancer patients undergoing primary radical surgery?”. Int. J. Gynecol. Cancer, 1999, 9, 28.

[13] Ayhan A., Yüce K., Tuncer Z.S., Urman B., Ayhan A.: “Stage I adenocarcinoma of the uterine cervix: tumor size, grade, lymph node metastases and 5-year survival”. Aust. N. Z. J. Obstet. Gynecol., 1989, 29, 443.

[14] Park J.Y., Kim D.Y., Kim J.H., Kim Y.M., Kim Y.T., Nam J.H.: “Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix”. Br. J. Cancer, 2010, 102, 1692.

[15] Ishikawa H., Nakanishi T., Inoue T., Kuzuya K.: “Prognostic factors of adenocarcinoma of the uterine cervix”. Gynecol. Oncol., 1999, 73, 42.

[16] Galic V., Herzog T.J., Lewin S.N., Neugut A.I., Burke W.M., Lu Y.S., et al.: “Prognostic significance of adenocarcinoma histology in women with cervical cancer”. Gynecol. Oncol., 2012, 125, 287.

[17] Huang YT., Wang CC., Tsai CS., Lai C.H., Chang T.C., Chou H.H., et al.: “Long-term outcome and prognostic factors for adenocarcinoma/adenosquamous carcinoma of cervix after definitive radiotherapy”. Int. J. Radiat. Oncol. Biol. Phys., 2011, 80, 429.

[18] Kasuya G., Ogawa K., Iraha S., Nagai Y., Hirakawa M., Toita T., et al.: “Postoperative radiotherapy for uterine cervical cancer: impact of lymph node and histological type on survival”. Anticancer Res., 2013, 33, 2199.

[19] Rudtanasudjatum K., Charoenkwan K., Khunamornpong S., Siriaunkgul S.: “Impact of histology on prognosis of patients with early-stage cervical cancer treated with radical surgery”. Int. J. Gynaecol. Obstet., 2011, 115, 183.

[20] Lee Y.Y., Choi C.H., Kim T.J., Lee J.W., Kim B.G., Lee J.H., Bae D. S.: “A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA”. Gy-necol. Oncol., 2011, 120, 439.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time